F. Gelsomino

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Background In the phase 2 multicohort CheckMate 142 study (NCT02060188), nivolumab plus low-dose (1 mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable safety...

S. Abdullaev ;

A. Memaj ;

M. Lei ;

Scott Kopetz , MD, PhD;

M. Overman ;

A. Hill ;

K. Wong ;

T. Andre ;

Eric Van Cutsem , MD, PhD;

Sara Lonardi ;

H. Lenz ;

F. Gelsomino ;

M. Aglietta ;

M. Morse ;

Ryan M. McDermott ;

M. Sawyer ;

A. Hendlisz ;

B. Neyns ;

07/02/2021

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

F. Gelsomino

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products